Sarah Holland — investor profile photo

Sarah Holland

Chief Business Officer at CDR-Life and President of the Swiss Healthcare Licensing Group

📍 Basel, Basel-Town, Switzerland🔄 Updated November 2026💼 2 investments📅 7 years investing🗓 Last invested Dec 2019
Angel investor🌍 Switzerland
2
Total investments
2
Early stage
0
Mid stage
0
Late stage
7y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer
Dec 2019
Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world. As an early employee you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast and fun. Our brand new Site Includes: State of the Art lab space & Equipment- Healthy Cafe, Outdoor Patio, State of the Art Gym/Yoga Studio, Lounge ( Pool Table/ Golf Simulator ), Free/Plentiful Parking and More! Join Us!
Board member
Dec 2019
We are a leading CDMO in the LBP industry, supporting our customers with microbiology know-how, process expertise and industry changing innovation From pre-clinical to commercialization, from start-up to multinational pharma company, with best-in-class process technologies, strictly anaerobic strain handling and the most experienced staff, Bacthera supports the LBP industry with CMC development services and large-scale manufacturing solutions. Contact us to learn more!
early stageBiotechnology
Experience · 4 entries
All (4)
Investments (2)
Board (2)
2019
Board Observer
Dec 2019
Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world. As an early employee you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast and fun. Our brand new Site Includes: State of the Art lab space & Equipment- Healthy Cafe, Outdoor Patio, State of the Art Gym/Yoga Studio, Lounge ( Pool Table/ Golf Simulator ), Free/Plentiful Parking and More! Join Us!
Board member
Dec 2019
We are a leading CDMO in the LBP industry, supporting our customers with microbiology know-how, process expertise and industry changing innovation From pre-clinical to commercialization, from start-up to multinational pharma company, with best-in-class process technologies, strictly anaerobic strain handling and the most experienced staff, Bacthera supports the LBP industry with CMC development services and large-scale manufacturing solutions. Contact us to learn more!
early stageBiotechnology
2015
Head of Europe, Asia and US West Coast, External Science & Partnering
Oct 2015
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
2010
Global Head, Strategic Partnering
Mar 2010
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Investor lists
Lists that match Sarah's portfolio